Navigation Links
Renhuang Announces Fiscal Year 2010 Guidance
Date:3/4/2010

HARBIN, China, March 4 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced revenue and net income guidance for fiscal year 2010 ("FY 2010") ending October 31, 2010.

Renhuang expects revenues for FY 2010 to be in the range of $54.7-$55.6 million, which represents a 26% to 28% increase over reported revenues of $43.4 million in fiscal year 2009. The Company expects FY 2010 net income to be in the range of $18.6-$18.9 million, up 26% to 28% from net income of $14.8 million in fiscal year 2009.

"We anticipate strong organic growth in the top- and bottom-line to be driven by our continued focus on higher margin product offerings and expanding our direct sales efforts," commented Mr. Shaoming Li, Renhuang's chairman and CEO. "As the leading supplier of Siberian Ginseng (Acanthopanax)-based products and with an extensive nationwide distribution network, we are confident in our ability to capitalize on China's rapidly growing pharmaceutical market and continue our track record of delivering robust growth. In addition, positive financial growth in the first quarter of fiscal 2010 strengthens our confidence in meeting our guidance for fiscal year 2010."

About Renhuang Pharmaceuticals, Inc.

Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, bio-pharmaceutical products, and botanical antibiotic and OTC TCMs through its extensive distribution network of over 3,000 distributors and more than 70 sales centers across 24 provinces in China.

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand and market acceptance of the Company's products, the Company's ability to meet its financial guidance, competition in the marketing and sales of its products, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company assumes no obligation and does not intend to update any forward-looking statements, except as required by law.

    For more information, please contact:

    Company Contact:
     Renhuang Pharmaceuticals, Inc.
     Ms. Portia Tan, IR Contact
     Phone: +86-451-5392-5461
     Email: ir@renhuang.com

    CCG Investor Relations:
     Ms. Lei Huang, Account Manager
     Phone: +1-646-833-3417 (New York)
     Email: lei.huang@ccgir.com
     Web:   http://www.ccgirasia.com

     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com

SOURCE Renhuang Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.ccgirasia.com

'/>"/>

SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016 Vestagen Technical Textiles, Inc., a medical ... healthcare and other demanding applications, today announced it has ... replaces Dale Pfost , PhD, who was serving ... also joining Vestagen,s Board of Directors. ® ... barrier technologies that combines fluid repellent, antimicrobial and breathability ...
(Date:2/8/2016)... Ill. , Feb. 8, 2016  Astellas Pharma Inc. ... announced the promotion of James Robinson as president, ... company,s operations in North and South America ... Astellas Pharma US, representing the commercial organization in ... in 2013. Masao Yoshida , who is ...
(Date:2/8/2016)... , Feb. 8, 2016  CTI BioPharma Corp. ... Company received written communication from the U.S. Food and ... FDA has placed a partial clinical hold on the ... Drug ("IND") application for pacritinib. This clinical hold impacts ... the IND and will also affect planned clinical trials. ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... According to research by the National ... technicians to be certified or obtain continuing education. To increase patient awareness of ... Your Mouth?” campaign to inform dentists and patients about the possible lack of ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced today ... the tools and information to lower the costs, and increase the impact of ... providing employee healthcare benefits by as much as 22%:, + Price and ...
(Date:2/6/2016)... ... ... US Sports Camps is proud to sponsor the Bay Area Disc Association's ... leaders, ultimate organizations, and coaches from around the US. The theme for this year’s ... of Youth and Education, describes this year YUCC as “an important conversation we must ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... eating disorder treatment helps to reduce the frequency and level of relapse. ... Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of the ...
(Date:2/5/2016)... ... 2016 , ... VeloReality President and co-founder Gary ... VR Indoor Trainer with multi-rider capability to an enthusiastic audience at the company's ... the weight of the unit, they also enhance the rider's experience with a ...
Breaking Medicine News(10 mins):